# South Korea Nontuberculous Mycobacteria Market > South Korea Nontuberculous Mycobacteria Market Research Report: Size, Share, Trend Analysis By Class of Drugs (Oral Antibiotics, IV Antibiotics, Anti-Nausea, Nebulized Antibiotics) - Growth Outlook & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 2.45% - **2024:** $ 233.7 Million - **2025:** $ 239.43 Million - **2035:** $ 305 Million - **Key Players:** Thermo Fisher Scientific (US), Merck KGaA (DE), Abbott Laboratories (US), Roche Holding AG (CH), Bio-Rad Laboratories (US), Qiagen N.V. (NL), Hologic, Inc. (US), Becton, Dickinson and Company (US) **Report ID:** MRFR/HC/50862-HCR · **Pages:** 200 · **Author:** Vikita Thakur & Rahul Gotadki · **Last Updated:** August 24, 2026 **URL:** https://www.marketresearchfuture.com/reports/south-korea-nontuberculous-mycobacteria-market-52621 --- ## Market Summary ## **South Korea Nontuberculous Mycobacteria Market Overview** As per MRFR analysis, the South Korea Nontuberculous Mycobacteria Market Size was estimated at 182.44 (USD Million) in 2023. The South Korea Nontuberculous Mycobacteria Market Industry is expected to grow from 187(USD Million) in 2024 to 248 (USD Million) by 2035. The South Korea Nontuberculous Mycobacteria Market CAGR (growth rate) is expected to be around 2.6% during the forecast period (2025 - 2035). **Key South Korea Nontuberculous Mycobacteria Market Trends Highlighted** The South Korea Nontuberculous Mycobacteria (NTM) market is influenced by several key market drivers, including the increasing prevalence of respiratory diseases, particularly among individuals with compromised immune systems and those exposed to environmental factors. As NTM infections gain recognition in clinical settings, healthcare providers are emphasizing early diagnosis and targeted therapies, driving the demand for innovative treatment options. Additionally, expanded access to healthcare services and advancements in diagnostic technologies have heightened awareness and detection rates for NTM diseases across the nation. Several opportunities can be harnessed within the South Korean market, particularly through research and development initiatives focused on novel antimicrobial therapies and vaccines.Collaborations between academic institutions, biotechnology firms, and pharmaceutical companies are essential to advance the understanding of NTM pathogens. Government support for research activities, as indicated by various health and science ministries, creates a conducive environment for innovations. Furthermore, public health initiatives aimed at improving infection control and prevention are critical areas where market players can contribute and benefit. Recent trends indicate a shift towards personalized medicine approaches in treating NTM infections, aligning with global healthcare trends. The introduction of targeted therapies and precision diagnostics reflects a growing commitment to enhancing patient outcomes. Moreover, South Korea's robust healthcare infrastructure and increasing technological proficiency position the country to lead in developing unique solutions to combat NTM-related health issues. As patient-centered care continues to become a priority, the focus on understanding the genetic makeup of NTM strains will likely shape future treatment protocols and clinical guidelines. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review **South Korea Nontuberculous Mycobacteria Market Drivers** **Increasing Incidence of Respiratory Diseases** The increased frequency of respiratory disorders is a major driver of the South Korea Nontuberculous Mycobacterium Market Industry. According to the Korea Disease Control and Prevention Agency, respiratory disorders made up around 19% of all ailments recorded in the country. As respiratory infections have increased, so have the number of people identified with nontuberculous mycobacterial infections, encouraging healthcare providers to seek improved diagnostic and treatment alternatives. The South Korea Nontuberculous Mycobacteria Market is expected to rise further as hospitals and clinics become more aware of the need for early identification and treatment of these infections. With government programs targeted at expanding healthcare access and illness management techniques, the need for specialised treatments in this area is likely to rise. Notable organizations, such as the Korean Society of Infectious Diseases, have advocated for more study on nontuberculous mycobacteria, which correlates with increased healthcare spending, hence boosting business growth. Furthermore, rising hospitalization rates owing to respiratory diseases are projected to increase demand for new therapies, underscoring the importance of focused market development. **Advancements in Diagnostic Technologies** The South Korea Nontuberculous Mycobacteria Market Industry is witnessing growth fueled by rapid advancements in diagnostic technologies. The South Korean government is actively investing in medical technology, with the Ministry of Health and Welfare announcing new funding initiatives to improve diagnostic accuracy. Technological improvements in Polymerase Chain Reaction (PCR) and sequencing methods have made it possible to more accurately detect nontuberculous mycobacterial infections, thereby enhancing treatment success rates. The increased efficiency and speed of these innovative diagnostics attract healthcare facilities, which significantly influences the demand in the market. Moreover, organizations like the Korean Association of Laboratory Professionals are pushing for modernizing laboratory techniques, contributing to a more streamlined process for diagnosis and treatment. With the backing of advancements in healthcare technology, the South Korea Nontuberculous Mycobacteria Market stands to capitalize on this trend over the coming years. **Growing Research and Development Initiatives** Robust Research and Development (R&D) initiatives in South Korea have become a key driver in the Nontuberculous Mycobacteria Market Industry. The South Korean government has increased its funding in healthcare R&D, reaching an investment of about 3.9% of the country's Gross Domestic Product, contributing to innovative therapeutic solutions against nontuberculous mycobacteria. Research institutions and pharmaceutical companies such as Samsung Biologics and LG Chem are heavily focused on developing novel treatment protocols and biologics for these infections.This concentrated focus on R&D is crucial as it can potentially result in breakthroughs in treatment methodologies. In addition, international collaborations in medical research, facilitated by Korean National Research Foundation, ensure access to a broader knowledge pool and resource-sharing, adding further momentum to R&D endeavors aimed at addressing nontuberculous mycobacterial diseases in South Korea. **South Korea Nontuberculous Mycobacteria Market Segment Insights** **Nontuberculous Mycobacteria Market Class of Drugs Insights** The South Korea Nontuberculous Mycobacteria Market experiences a significant focus on the Class of Drugs segment, which is vital for the treatment of a range of diseases caused by nontuberculous mycobacteria. This market comprises various therapeutic options, including Oral Antibiotics, IV Antibiotics, Anti Nausea medications, and Nebulized Antibiotics, each playing a crucial role in patient management strategies. Oral Antibiotics have gained considerable attention due to their convenience and ease of administration, making them a preferred choice for outpatient treatment, thus enhancing patient compliance. IV Antibiotics, while more challenging to administer due to the requirement of skilled personnel, cater to severe cases of nontuberculous mycobacterial infections and are vital for patients who are hospitalized or have a compromised immune system. Anti Nausea drugs are integral in managing the side effects associated with antibiotic therapies, ensuring that patients can tolerate their treatment regimens effectively. Furthermore, Nebulized Antibiotics provide a critical route of administration for patients with respiratory manifestations of the disease, enhancing local delivery to the site of infection and offering a targeted therapeutic approach.The demand for these therapeutic classes is propelled by an overall increase in awareness about nontuberculous mycobacterial diseases and advancements in treatment protocols, particularly in the South Korean healthcare sector. This demand is further supported by ongoing Research and Development aimed at improving existing therapies and reducing resistance rates. As the incidence of nontuberculous mycobacterial infections continues to rise, healthcare providers in South Korea are prioritizing these drug classes, reflecting a trend towards more effective and patient-centric treatment strategies that cater to the unique challenges posed by these infections. The South Korean government has also been active in developing guidelines and treatment standards that underscore the importance of these classes in achieving better patient outcomes. With this backdrop, the Class of Drugs segment within the South Korea Nontuberculous Mycobacteria Market is poised for continued relevance and significance as healthcare systems evolve to meet the needs of this patient population. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review **South Korea Nontuberculous Mycobacteria Market Key Players and Competitive Insights** The South Korea Nontuberculous Mycobacteria Market represents a vital segment in the broader healthcare and biotechnology landscape, characterized by its unique challenges and opportunities. This market is influenced by increasing incidences of respiratory diseases related to nontuberculous mycobacteria, heightened awareness of diagnosis and treatment options, and advancements in medical technologies. Key players in this market are actively engaged in research and development to address these issues and to provide effective therapies. The competitive landscape is shaped by a mix of established pharmaceutical firms and emerging biotechnology companies focused on the development of innovative solutions tailored to the needs of patients suffering from conditions associated with nontuberculous mycobacteria. The dynamics of this market are further shaped by regulatory requirements, pricing strategies, and competitive collaborations aimed at enhancing treatment availability and patient outcomes.Celltrion holds a significant position in the South Korea Nontuberculous Mycobacteria Market, known for its robust research and development capabilities. The company has established a strong presence through its focus on addressing unmet medical needs, particularly in the field of infectious diseases. Celltrion's strengths lie in its advanced biomanufacturing processes, which enable the production of high-quality biological products. The company’s commitment to innovation has facilitated the development of therapies aimed at managing conditions related to nontuberculous mycobacteria. Its emphasis on partnerships and collaborations with healthcare organizations has further strengthened its market capacity, positioning Celltrion as a key competitor capable of providing effective treatment alternatives and influencing market trends within the South Korean healthcare sector.LG Chem is another influential player within the South Korea Nontuberculous Mycobacteria Market, recognized for its comprehensive portfolio that includes pharmaceuticals, diagnostic products, and therapeutic solutions. The company leverages its extensive research capabilities and manufacturing expertise to develop biologics aimed at addressing respiratory diseases linked to nontuberculous mycobacteria. LG Chem’s strengths lie in its innovative approaches to drug development, which are supported by significant investments in research and development. Additionally, the company has actively pursued mergers and acquisitions to enhance its product offerings and market presence in South Korea, thereby expanding its capabilities within the healthcare sector. LG Chem's focus on collaboration with other bioscience companies and research institutions further illustrates its commitment to advancing treatment options, ensuring it remains a competitive force in the South Korean Nontuberculous Mycobacteria Market. **Key Companies in the South Korea Nontuberculous Mycobacteria Market Include** - Celltrion - LG Chem - Hanmi Pharmaceutical - Daewoong Pharmaceutical - Yuhan Corporation - Green Cross - Hugel - Samsung Biologics - Genexine - CJ HealthCare - Medytox - Korea Company - SK Bioscience - Korea Vaccine - SL Pharma **South Korea Nontuberculous Mycobacteria Market Industry Developments** In recent months, the South Korea Nontuberculous Mycobacteria Market has seen significant developments, particularly in the areas of research and investment. Companies such as Celltrion and LG Chem are reportedly expanding their efforts in the development of treatments for Nontuberculous Mycobacteria infections. Moreover, Hanmi Pharmaceutical is advancing its clinical trials for new therapeutics aimed at addressing these infectious diseases, reflecting the increasing emphasis on combating antimicrobial resistance. Current affairs in this market remain focused on collaborations and advancements in biotechnology. Samsung Biologics continues to explore partnerships for the manufacture of biologics targeting Nontuberculous Mycobacteria, aiming to ramp up production capacities to meet growing demands. In terms of mergers and acquisitions, there have been discussions among companies like Yuhan Corporation and Daewoong Pharmaceutical, with potential consolidation in the pipeline as they seek to leverage their resources for better synergy in drug development.The South Korean government is also enhancing its support for healthcare innovation, fostering an environment conducive to growth within the Nontuberculous Mycobacteria sector. Overall, the market trajectory suggests a heightened commitment to combating these infections, with robust support from both private and public sectors. **South Korea Nontuberculous Mycobacteria Market Segmentation Insights** **Nontuberculous Mycobacteria Market Class of Drugs****Outlook** - Oral Antibiotics - IV Antibiotics - Anti Nausea - Nebulized Antibiotics ## Market Drivers ### Rising Healthcare Expenditure The increasing healthcare expenditure in South Korea is a crucial driver for the nontuberculous mycobacteria market. As the government allocates more funds towards healthcare services, there is a corresponding rise in the availability of advanced diagnostic and treatment options for infectious diseases. In 2025, healthcare spending is expected to account for about 8% of the GDP, which may facilitate better access to therapies for nontuberculous mycobacterial infections. This trend suggests a growing market potential as patients gain access to improved healthcare services. ### Advancements in Diagnostic Technologies Advancements in diagnostic technologies are expected to significantly influence the nontuberculous mycobacteria market. The introduction of rapid and accurate diagnostic tools, such as molecular assays and next-generation sequencing, may enhance the detection of nontuberculous mycobacterial infections. These innovations could lead to earlier diagnosis and treatment, improving patient outcomes. The market for diagnostic technologies in infectious diseases is projected to grow by 10% annually, indicating a strong potential for the nontuberculous mycacteria market as these technologies become more widely adopted. ### Growing Public Health Awareness Campaigns Public health awareness campaigns in South Korea are likely to play a pivotal role in driving the nontuberculous mycobacteria market. These campaigns aim to educate the population about the risks associated with nontuberculous mycobacterial infections and the importance of early diagnosis and treatment. As awareness increases, more individuals may seek medical attention, leading to higher demand for diagnostic tests and therapies. The potential impact of these campaigns could result in a market growth of approximately 6% over the next few years, as public engagement translates into increased healthcare utilization. ### Enhanced Research and Development Activities The nontuberculous mycobacteria market is likely to benefit from enhanced research and development activities in South Korea. With a growing emphasis on understanding the pathogenicity and treatment of nontuberculous mycobacteria, pharmaceutical companies are investing significantly in R&D. This investment is expected to yield innovative therapies and diagnostic tools, potentially increasing market value. In 2025, the R&D expenditure in the healthcare sector is projected to reach approximately $5 billion, indicating a robust commitment to addressing infectious diseases, including those caused by nontuberculous mycobacteria. ### Increasing Incidence of Respiratory Diseases The rising incidence of respiratory diseases in South Korea appears to be a significant driver for the nontuberculous mycobacteria market. Reports indicate that conditions such as chronic obstructive pulmonary disease (COPD) and bronchiectasis are becoming more prevalent, leading to a heightened awareness of nontuberculous mycobacterial infections. This trend may result in increased diagnostic testing and treatment options, thereby expanding the market. The healthcare system's focus on managing these respiratory conditions could potentially lead to a market growth rate of around 7% annually, as more patients seek effective therapies for their ailments. ## Future Outlook The [Nontuberculous Mycobacteria Market](https://www.marketresearchfuture.com/reports/nontuberculous-mycobacteria-market-16170) in South Korea is projected to grow at a 2.45% CAGR from 2025 to 2035, driven by increasing awareness and advancements in diagnostic technologies. **New opportunities:** - Development of targeted therapies for specific nontuberculous mycobacterial infections. Expansion of telehealth services for remote patient monitoring and consultations. Investment in advanced diagnostic tools to enhance early detection and treatment efficacy. By 2035, the market is expected to demonstrate robust growth and increased innovation. ## Segment Insights ### By Class of Drugs: Oral Antibiotics (Largest) vs. IV Antibiotics (Fastest-Growing) In the South Korea nontuberculous mycobacteria market, Oral Antibiotics hold a significant portion of the market share, serving as the preferred initial treatment for many patients. Their established efficacy and ease of administration contribute to their dominance, making them a go-to option for healthcare providers. Meanwhile, IV Antibiotics have emerged as crucial alternatives, especially in severe cases requiring immediate intervention, thereby capturing a rapidly increasing market segment. Growth in this segment is driven by rising awareness of nontuberculous mycobacterial infections among healthcare professionals and the growing number of drug-resistant strains. This awareness has spurred the development of novel formulations and delivery methods, especially for IV Antibiotics. The push for improved patient outcomes will continue to propel these segments forward, with ongoing clinical trials likely to create further innovations and options for treatment. Oral Antibiotics: Dominant vs. IV Antibiotics: Emerging Oral Antibiotics are characterized by their ease of use and patient compliance, often prescribed as a first-line treatment in outpatient settings. Their established role in managing nontuberculous mycobacterial infections makes them the dominant force in the market. On the other hand, IV Antibiotics, although currently viewed as an emerging solution, are becoming crucial for patients with severe conditions or those who are unable to tolerate oral medications. The shift towards IV administration reflects a growing recognition of the need for effective treatment in challenging cases, positioning IV Antibiotics to address unmet medical needs and expanding their market presence. ## Competitive Benchmarking The [nontuberculous mycobacteria market](https://www.marketresearchfuture.com/reports/nontuberculous-mycobacteria-market-16170) in South Korea is characterized by a competitive landscape that is increasingly shaped by innovation and strategic partnerships. Key players such as Thermo Fisher Scientific (US), Merck KGaA (DE), and Abbott Laboratories (US) are actively pursuing strategies that emphasize technological advancements and regional expansion. For instance, Thermo Fisher Scientific (US) has focused on enhancing its diagnostic capabilities, which appears to position the company favorably in a market that demands rapid and accurate testing solutions. Meanwhile, Merck KGaA (DE) has been investing in research and development to expand its product portfolio, indicating a commitment to maintaining a competitive edge through innovation. Abbott Laboratories (US) has also been enhancing its operational focus on digital transformation, which may streamline processes and improve customer engagement, thereby shaping the competitive dynamics of the market.The business tactics employed by these companies reflect a concerted effort to optimize supply chains and localize manufacturing. The market structure is moderately fragmented, with several players vying for market share, yet the influence of major companies is palpable. This competitive environment suggests that while there is room for smaller entities, the strategic maneuvers of larger firms are likely to dictate market trends and consumer preferences. In October Roche Holding AG (CH) announced a collaboration with a local South Korean biotech firm to develop a novel diagnostic tool for nontuberculous mycobacterial infections. This partnership is strategically significant as it not only enhances Roche's product offerings but also allows for localized expertise in addressing specific regional health challenges. Such collaborations may lead to more tailored solutions that resonate with healthcare providers and patients alike. In September Bio-Rad Laboratories (US) launched a new line of reagents specifically designed for the detection of nontuberculous mycobacteria. This product introduction is indicative of Bio-Rad's commitment to innovation and reflects a broader trend of companies investing in specialized diagnostic tools. The strategic importance of this launch lies in its potential to capture market share by meeting the growing demand for precise diagnostic solutions in the region. As of November the competitive trends in the nontuberculous mycobacteria market are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence (AI) into diagnostic processes. Strategic alliances are becoming more prevalent, as companies recognize the value of collaboration in enhancing their technological capabilities. Looking ahead, it appears that competitive differentiation will increasingly pivot from traditional price-based competition to a focus on innovation, technological advancements, and the reliability of supply chains. This shift may ultimately redefine how companies position themselves in the market, emphasizing the importance of adaptability and forward-thinking strategies. ## Recent News & Developments In recent months, the South Korea Nontuberculous Mycobacteria Market has seen significant developments, particularly in the areas of research and investment. Companies such as Celltrion and LG Chem are reportedly expanding their efforts in the development of treatments for Nontuberculous Mycobacteria infections. Moreover, Hanmi Pharmaceutical is advancing its clinical trials for new therapeutics aimed at addressing these infectious diseases, reflecting the increasing emphasis on combating antimicrobial resistance. Current affairs in this market remain focused on collaborations and advancements in biotechnology. Samsung Biologics continues to explore partnerships for the manufacture of biologics targeting Nontuberculous Mycobacteria, aiming to ramp up production capacities to meet growing demands. In terms of mergers and acquisitions, there have been discussions among companies like Yuhan Corporation and Daewoong Pharmaceutical, with potential consolidation in the pipeline as they seek to leverage their resources for better synergy in drug development.The South Korean government is also enhancing its support for healthcare innovation, fostering an environment conducive to growth within the Nontuberculous Mycobacteria sector. Overall, the market trajectory suggests a heightened commitment to combating these infections, with robust support from both private and public sectors. ## Report Scope | MARKET SIZE 2024 | 233.7(USD Million) | | --- | --- | | MARKET SIZE 2025 | 239.43(USD Million) | | MARKET SIZE 2035 | 305.0(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 2.45% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | Thermo Fisher Scientific (US), Merck KGaA (DE), Abbott Laboratories (US), Roche Holding AG (CH), Bio-Rad Laboratories (US), Qiagen N.V. (NL), Hologic, Inc. (US), Becton, Dickinson and Company (US) | | Segments Covered | Class of Drugs | | Key Market Opportunities | Advancements in diagnostic technologies enhance early detection in the nontuberculous mycobacteria market. | | Key Market Dynamics | Rising awareness and regulatory scrutiny drive innovation in nontuberculous mycobacteria diagnostics and treatment solutions. | | Countries Covered | South Korea | ## Frequently Asked Questions **Q: What was the market valuation for nontuberculous mycobacteria in South Korea in 2024?** A: The market valuation for nontuberculous mycobacteria in South Korea was $233.7 Million in 2024. **Q: What is the projected market valuation for nontuberculous mycobacteria in South Korea by 2035?** A: The projected market valuation for nontuberculous mycobacteria in South Korea is $305.0 Million by 2035. **Q: What is the expected CAGR for the South Korea nontuberculous mycobacteria market during the forecast period 2025 - 2035?** A: The expected CAGR for the South Korea nontuberculous mycobacteria market during the forecast period 2025 - 2035 is 2.45%. **Q: Which companies are considered key players in the South Korea nontuberculous mycobacteria market?** A: Key players in the South Korea nontuberculous mycobacteria market include Thermo Fisher Scientific, Merck KGaA, Abbott Laboratories, Roche Holding AG, Bio-Rad Laboratories, Qiagen N.V., Hologic, Inc., and Becton, Dickinson and Company. **Q: What are the main segments of the South Korea nontuberculous mycobacteria market?** A: The main segments of the South Korea nontuberculous mycobacteria market include Oral Antibiotics, IV Antibiotics, Anti Nausea, and Nebulized Antibiotics. **Q: What was the valuation of Oral Antibiotics in the South Korea nontuberculous mycobacteria market in 2024?** A: The valuation of Oral Antibiotics in the South Korea nontuberculous mycobacteria market was $70.0 Million to $90.0 Million in 2024. **Q: What is the projected valuation range for IV Antibiotics in the South Korea nontuberculous mycobacteria market by 2035?** A: The projected valuation range for IV Antibiotics in the South Korea nontuberculous mycobacteria market by 2035 is $60.0 Million to $80.0 Million. **Q: How did the valuation of Anti Nausea products in the South Korea nontuberculous mycobacteria market change from 2024 to 2035?** A: The valuation of Anti Nausea products in the South Korea nontuberculous mycobacteria market was $50.0 Million to $65.0 Million in 2024 and is expected to increase by 2035. **Q: What is the expected valuation for Nebulized Antibiotics in the South Korea nontuberculous mycobacteria market by 2035?** A: The expected valuation for Nebulized Antibiotics in the South Korea nontuberculous mycobacteria market by 2035 is projected to be between $53.7 Million and $70.0 Million. **Q: How does the growth of the South Korea nontuberculous mycobacteria market compare to other regions?** A: While specific comparisons to other regions are not provided, the South Korea nontuberculous mycobacteria market is expected to grow steadily at a CAGR of 2.45% from 2025 to 2035. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/south-korea-nontuberculous-mycobacteria-market-52621*